Pharmaceuticals, Biotechnology and Life Sciences
Örn Almarsson named Chief Technology Officer Phase I trial for ultra-long-acting oral therapy for schizophrenia completes dosing 28% employee growth…
LONDON–(BUSINESS WIRE)–#ActivePharmaceuticalIngredientsMarket–Technavio has been monitoring the active pharmaceutical ingredients market and it is poised to grow by USD 60.56 billion…
Opdivo demonstrated superior overall survival benefit compared to docetaxel or paclitaxel1 First approved immunotherapy in this patient population regardless of…
Opdivo demonstrated superior overall survival benefit compared to docetaxel or paclitaxel1 First approved immunotherapy in this patient population regardless of…
Opdivo demonstrated superior overall survival benefit compared to docetaxel or paclitaxel1 First approved immunotherapy in this patient population regardless of…
Opdivo demonstrated superior overall survival benefit compared to docetaxel or paclitaxel1 First approved immunotherapy in this patient population regardless of…
DANBURY, Conn. & RESEARCH TRIANGLE PARK, N.C.–(BUSINESS WIRE)–IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV) today announced that its wholly owned subsidiary, IQVIA…
DANBURY, Conn. & RESEARCH TRIANGLE PARK, N.C.–(BUSINESS WIRE)–IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV) today announced that its wholly owned subsidiary, IQVIA…
DANBURY, Conn. & RESEARCH TRIANGLE PARK, N.C.–(BUSINESS WIRE)–IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV) today announced that its wholly owned subsidiary, IQVIA…
DANBURY, Conn. & RESEARCH TRIANGLE PARK, N.C.–(BUSINESS WIRE)–IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV) today announced that its wholly owned subsidiary, IQVIA…